RT Journal Article
SR Electronic
T1 New advances in the management of juvenile idiopathic arthritis—2: The era of biologicals
JF Archives of disease in childhood - Education & practice edition
JO Arch Dis Child Educ Pract Ed
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP 151
OP 156
DO 10.1136/adc.2009.170860
VO 94
IS 5
A1 M W Beresford
A1 E M Baildam
YR 2009
UL http://ep.bmj.com/content/94/5/151.abstract
AB Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA.The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra.National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paediatric rheumatic disorders.This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.